FDMT
4D Molecular Therapeutics Inc
14.50$
-1.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.0% | +85.3% | -1.6% | -2.6% | -7.2% | -8.0% | -8.2% | -10.5% | +33.7% | -9.5% | -4.0% | |
| – | -9.6% | +80.6% | +3.2% | -7.6% | -14.8% | -23.5% | -8.8% | +3.0% | +32.3% | -1.9% | -5.5% | |
| – | -9.6% | +10.6% | -31.4% | -0.8% | -20.4% | -10.6% | -42.2% | -37.1% | +24.1% | +20.3% | -2.9% | |
| – | -9.8% | +82.5% | +3.0% | -7.4% | -15.3% | -24.3% | -8.8% | +4.0% | +32.0% | -2.9% | -7.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.2% | -8.5% | +8.4% | +60.7% | -2.5% | -7.6% | +14.7% | +4.3% | +11.0% | +0.0% | +39.1% | |
| – | +4.3% | -13.4% | +18.3% | +51.9% | -1.1% | -7.7% | +28.9% | +7.0% | +18.5% | -1.3% | +9.8% | |
| – | +0.7% | +0.8% | +0.7% | +59.3% | +10.7% | +0.7% | +0.7% | -0.5% | -1.8% | -1.9% | -2.0% | |
| – | -25.4% | +20.0% | -18.6% | -14.8% | +50.0% | -5.4% | +109.6% | -21.1% | +62.6% | +31.7% | -14.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6.7% | +95.1% | -2.0% | -6.0% | -7.7% | -8.0% | -10.4% | -12.3% | +37.0% | -10.6% | -9.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -7.4% | +25.9% | +12.2% | +0.5% | -2.9% | +3.3% | +0.3% | +0.4% | +3.2% | +17.5% | +3.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.